Ani Pharmaceuticals (ANIP) Share-based Compensation (2010 - 2026)

Ani Pharmaceuticals has reported Share-based Compensation for 17 years, with the latest figure at $10.2 million in Q1 2026.

• Quarterly Share-based Compensation rose 14.92% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (down 74.54% YoY) and the FY2025 annual result came in at $6.6 million, down 77.37% from the prior year.
• Share-based Compensation rose to $10.2 million in Q1 2026 per ANIP's latest filing, from $1.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $10.2 million in Q1 2026 and troughed at -$13.2 million in Q3 2025.
• A 5-year average of $3.7 million and a median of $4.3 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 4784.47% in 2024, then tumbled 276.7% in 2025.
• Over 5 years, Share-based Compensation stood at $483000.0 in 2022, then plunged by 55.28% to $216000.0 in 2023, then surged by 3168.98% to $7.1 million in 2024, then slumped by 80.22% to $1.4 million in 2025, then surged by 629.49% to $10.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $10.2 million, $1.4 million, and -$13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.